Table 2.
Treatment-related adverse events in the posttreatment period experienced by ≥5% of NAb+participants.
| AE by preferred term | Participants with an AE (n = 21), n (%) | No. of events |
|---|---|---|
| Participants with at least 1 treatment-related AE | 15 (71.4) | 36 |
| Influenza-like illness | 4 (19.0) | 4 |
| ALT increased | 3 (14.3) | 3 |
| IRR | 5 (23.8) | 5 |
| ALP increased | 2 (9.5) | 2 |
| CRP increased | 2 (9.5) | 2 |
| Headache | 2 (9.5) | 2 |
| Nausea | 2 (9.5) | 2 |
AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; CRP, C-reactive protein; IRR, infusion-related reaction; NAb+, neutralizing antibody-positive.